Glyoxalase I inhibitor 5 (Compound 9h) is a potent inhibitor of glyoxalase I (Glo-I), with an IC50 value of 1.28 μM. This compound holds promise as an anticancer agent [1].
Glyoxalase I inhibitor 7 (Compound 6) is a potent inhibitor of glyoxalase I (Glo-I) with an IC50 of 3.65 μM. It exhibits potential as an anticancer agent [1].
Glyoxalase I inhibitor 6 (Compound 9j) is an inhibitor of glyoxalase I (Glo-I) with an IC50 value of 1.13 μM. This compound shows potential as an anticancer agent, demonstrating low toxicity [1].
COTC is a bacterial metabolite that has anticancer activity and inhibits glyoxalase in the presence of glutathione (GSH) and the proliferation of HeLa cells, as well as reduces tumor growth and improves survival in an Ehrlich murine spontaneous adenocarcinoma model.
Isolupalbigenin shows promising cytotoxic effects toward HL-60 cells (IC50 4.3 ± 0.7 to 18.0 ± 1.7 uM), it also shows in vitro inhibitory activity toward human glyoxalase I. Isolupalbigenin shows two different antibacterial activities against MRSA: direct growth inhibition and intensification of methicillin sensitivity, it could lead to the development of compounds for new approaches against MRSA infection.